Francesca Pucci

Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

Chiara Cremolini, Daniele Rossini, Emanuela Dell’Aquila et al. · JAMA Oncology · 2018 · 397 citations · Full text

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 309 citations · Full text

Oncology, Medicine, Colorectal Cancer +8

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer

Emilio Bajetta, Irene Floriani, Maria Di Bartolomeo et al. · Annals of Oncology · 2014 · 89 citations · Full text

Surgical Oncology, Oncology, Gastrointestinal Oncology +10

Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy

Francesca Negri, Nicoletta Campanini, R. Camisa et al. · British Journal of Cancer · 2007 · 82 citations · Full text

Pathology, Biological Predictive Factors, Microsatellite Instability +17

Everolimus in combination with octreotide long‐acting repeatable in a first‐line setting for patients with neuroendocrine tumors: An ITMO group study

Emilio Bajetta, Laura Catena, Nicola Fazio et al. · Cancer · 2014 · 74 citations